Sorivudine

Structural formula
General
Non-proprietary name	Sorivudine
other names	( E ) -5- (2-bromovinyl) uridine; ( E ) -5- (2-bromovinyl) -1β- D -arabinofuranosyluracil; 5 - [( E ) -2-bromoethenyl] -1 - [(2 R , 3 S , 4 S , 5 R ) -3,4-dihydroxy-5- (hydroxymethyl) oxolan-2-yl] pyrimidin-2, 4-dione;
Molecular formula	C 11 H 13 BrN 2 O 6
External identifiers / databases
PubChem	5282192
Wikidata	Q905418
Drug information
ATC code	J05 AB15
Drug class	Antiviral
properties
Molar mass	349.13 g mol −1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Sorivudine is an anti -viral drug from the Japanese company Nippon Shoji , which was used to treat herpes zoster infections (shingles), herpes simplex type 1 and Epstein-Barr virus . Several deaths in patients treated simultaneously with sorivudine and fluorouracil sparked a pharmaceutical scandal in Japan in 1994. The commercial preparation Usevir ^® is no longer on the market in Japan.

application

Sorivudine is an inhibitor of the fluorouracil- degrading enzyme dihydropyrimidine dehydrogenase (DPD), which can lead to the lethal accumulation of fluorouracil administered at the same time.

Sorivudine, like brivudine , is broken down in the body into the metabolite bromovinyluracil (BVU).

Bromovinyluracil

Deaths

The deaths of 16 sorivudine-treated patients sparked a drug scandal in Japan in 1994 . Three patients had already died during the clinical trials of sorivudine. Since Sorivudine inventor Nihon Shoji had submitted misleading and inaccurate data to the Japanese Ministry of Health and Welfare (MHW), Sorivudine was approved. It was later revealed that Nihon Shoji employees sold off their shares before the link between sorivudine and the deaths was reported in the press.

Web links

Drugs containing 5-fluorouracil or 5-fluoropyrimidine derivatives for systemic use, interaction with brivudine and phenytoin, step-by-step plan procedure stage II. BfArM , April 10, 2007, accessed on May 2, 2017 .

literature

RB Diasio: Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase . In: Br J Clin Pharmacol . tape 46 , no. 1 , July 1998, pp. 1–4 , doi : 10.1046 / j.1365-2125.1998.00050.x , PMC 1873978 (free full text).
H. Gurdon: Japan bans shingles drug after deaths . In: The BMJ . tape 309 , September 1994, p. 627 , doi : 10.1136 / bmj.309.6955.627 .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ ABDA database (as of December 4, 2009).
^ Brian Woodall, Aki Yoshikawa: Japan's Failure in Pharmaceuticals: Why Is the World Saying "No" to Japanese Drugs? ( August 31, 2000 memento on the Internet Archive ) Georgia Institute of Technology, Yoshikawa Stanford University, March 1997.

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] ABDA database (as of December 4, 2009).

[BWGIOT-1997-03-3] Brian Woodall, Aki Yoshikawa: Japan's Failure in Pharmaceuticals: Why Is the World Saying "No" to Japanese Drugs? ( August 31, 2000 memento on the Internet Archive ) Georgia Institute of Technology, Yoshikawa Stanford University, March 1997.